M.D. Anderson Cancer Center
To learn if the combination of enfortumab vedotin plus radiation therapy could help to control the disease.
Primary Objectives: 1. Primary Objective #1: To estimate progression free survival for concurrent enfortumab vedotin with RT in locally advanced MIBC 2. Primary Objective #2: To evaluate the safety/tolerability of enfortumab vedotin with RT in participants with locally advanced MIBC 3. Primary Objective #3: To evaluate global health-related quality of life (HRQOL) using EQ-5D-5L, EORTC MIBC module, and EPIC bowel domain surveys Secondary Objectives: 1. Secondary Objective #1: To estimate the overall survival at 12 months after study enrollment. 2. Secondary Objective #2: To estimate the met…
Inclusion Criteria: 1. Pathologically confirmed diagnosis of urothelial carcinoma of the bladder including patients with T4N0 and T1-4N2-3 disease. Participants with mixed urothelial carcinoma of bladder will also be included. 2. Be ≥ 18 years of age on the day of signing informed consent. 3. ECOG performance status 0-2. NOTE: If participants is unable to walk due to paralysis, but is mobile in a wheelchair, participants is ambulatory for the purpose of assessing their performance status. 4. The participant has the following baseline laboratory data: 1. Hemoglobin ≥ 9 g/dL 2. Platelet…
Given by IV
Given by Radiation Therapy
Arctuva estimate
Verify or correct the compensation shown for this listing.